Middle East Pharmaceutical Industries Company (TADAWUL: 4016)
Saudi Arabia
· Delayed Price · Currency is SAR
118.60
-1.60 (-1.33%)
Dec 19, 2024, 3:19 PM AST
Middle East Pharmaceutical Industries Company Cash Flow Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 80.44 | 65.83 | 59.45 | 66.28 | 72.81 |
Depreciation & Amortization | 8.93 | 7.61 | 6.84 | 6.7 | 6.69 |
Other Amortization | 5.16 | 4.32 | 3.78 | 2.87 | 2.17 |
Loss (Gain) From Sale of Assets | -0.59 | -0.13 | -0.08 | 0.03 | 0 |
Asset Writedown & Restructuring Costs | 0.45 | 0.45 | 0.06 | - | - |
Loss (Gain) From Sale of Investments | - | - | - | 2.76 | - |
Provision & Write-off of Bad Debts | 2.36 | -1.51 | 0.13 | - | 2 |
Other Operating Activities | 4.23 | 5.77 | 7.91 | -0.88 | 1.01 |
Change in Accounts Receivable | -33.94 | -2.44 | 12.66 | -54.5 | 2.4 |
Change in Inventory | -10.87 | 12.45 | -27.38 | 8.19 | -41.31 |
Change in Accounts Payable | 5.22 | -9.91 | 5.22 | 6.53 | -0.54 |
Change in Other Net Operating Assets | 0.14 | 10.22 | -0.03 | 2.74 | -0.82 |
Operating Cash Flow | 61.54 | 92.66 | 68.57 | 40.72 | 44.42 |
Operating Cash Flow Growth | -16.76% | 35.14% | 68.40% | -8.33% | - |
Capital Expenditures | -19.7 | -20.83 | -9.58 | -15.43 | -33 |
Sale of Property, Plant & Equipment | 0.14 | 0.14 | 0.41 | 0.04 | 0.01 |
Divestitures | - | - | - | - | -0.17 |
Sale (Purchase) of Intangibles | -9.63 | -10.14 | -11.03 | -9.25 | -6.57 |
Investment in Securities | - | - | - | -0.17 | -22.72 |
Investing Cash Flow | -29.19 | -30.83 | -20.2 | -24.8 | -62.46 |
Short-Term Debt Issued | - | 174.13 | 121.94 | - | - |
Long-Term Debt Issued | - | - | - | 83.52 | 125.3 |
Total Debt Issued | 173.18 | 174.13 | 121.94 | 83.52 | 125.3 |
Short-Term Debt Repaid | - | -192.99 | -119.25 | - | - |
Long-Term Debt Repaid | - | -6.34 | -4.75 | -59.13 | -75.21 |
Total Debt Repaid | -175.31 | -199.33 | -124 | -59.13 | -75.21 |
Net Debt Issued (Repaid) | -2.13 | -25.2 | -2.06 | 24.38 | 50.09 |
Common Dividends Paid | -27 | -36 | -36.35 | -37.2 | -36.26 |
Other Financing Activities | 2.05 | -9.31 | -5.2 | - | - |
Financing Cash Flow | -27.07 | -70.51 | -43.61 | -12.82 | 13.83 |
Miscellaneous Cash Flow Adjustments | - | - | - | 0.01 | - |
Net Cash Flow | 5.28 | -8.68 | 4.76 | 3.11 | -4.21 |
Free Cash Flow | 41.84 | 71.82 | 58.99 | 25.28 | 11.42 |
Free Cash Flow Growth | -31.84% | 21.76% | 133.30% | 121.46% | - |
Free Cash Flow Margin | 10.81% | 21.22% | 19.49% | 8.80% | 3.78% |
Free Cash Flow Per Share | 2.09 | 3.59 | 2.95 | 1.26 | 0.57 |
Cash Interest Paid | 4.33 | 4.33 | 3.93 | - | - |
Levered Free Cash Flow | - | 31.49 | 22.98 | -6.24 | - |
Unlevered Free Cash Flow | - | 35.08 | 25.94 | -5.08 | - |
Change in Net Working Capital | - | -5.67 | 7.45 | 37.57 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.